<html>
   <body>
      <div id="contentsscroll">
         <div id="title">
            <h2>
               "Point in Time" Regulation Content
            </h2>
            <h4>
               <em>
                  Pharmaceutical Services Act
               </em>
            </h4>
            <h3 style="line-height: 110%">
               Drug Price Regulation
            </h3>
            <h3>
               B.C. Reg. 344/2012
            </h3>
         </div>
         <div id="contentpit">
            <table border="0" cellpadding="3" cellspacing="0">
               <tbody>
                  <tr>
                     <td class="smalltext" colspan="2">
                        NOTE:
                        <em>
                           Links below go to regulation content								as it was prior to the changes made on the effective date. (PIT
								covers changes made from September 19, 2009 to
								"current to" date of the regulation.)
                        </em>
                     </td>
                  </tr>
                  <tr>
                     <th>
                        SECTION
                     </th>
                     <th class="sec">
                        EFFECTIVE DATE
                     </th>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                        Section 1
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit1">
                           April 1, 2017
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit2">
                           April 1, 2019
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                        Section 3
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit3">
                           April 1, 2019
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                        Section 3.01
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit4">
                           April 1, 2019
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                        Section 3.1
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit5">
                           April 1, 2017
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit6">
                           April 1, 2019
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                        Section 4
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit7">
                           April 1, 2014
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit8">
                           April 1, 2019
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                        Section 5
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit9">
                           April 1, 2014
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit10">
                           April 1, 2019
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                        Section 6
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit11">
                           January 1, 2016
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                        Section 14
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit12">
                           April 1, 2017
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit13">
                           April 1, 2019
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                        Section 15
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit14">
                           April 1, 2017
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit15">
                           April 1, 2019
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                        Section 17
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit16">
                           March 1, 2014
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit17">
                           January 29, 2016
                        </a>
                     </td>
                  </tr>
                  <tr>
                     <td align="center" valign="top">
                        Part 4
                     </td>
                     <td align="center" class="sec" valign="top" width="60%">
                        <a href="#pit18">
                           April 1, 2017
                        </a>
                     </td>
                  </tr>
               </tbody>
            </table>
         </div>
         <div id="mainpit">
            <div class="pitfirst" width="100%">
               <p class="reference">
                  <a name="pit1">
                  </a>
                  Section 1 (1) definitions "designation period" and "exclusive generic drug" were added by BC Reg 266/2016, effective April 1, 2017.
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit2">
                  </a>
                  Section 1 (1) definitions "designation period" and "exclusive generic drug" BEFORE repealed by BC Reg 22/2019, effective April 1, 2019.
               </p>
               <p class="def" id="d0e155" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <span class="normal-bold-style" id="designation+period">
                     "designation period"
                  </span>
                  means the specified period for which a generic drug is designated as an exclusive generic drug for an LCA category;
               </p>
               <p class="def" id="d0e164" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <span class="normal-bold-style" id="exclusive+generic+drug">
                     "exclusive generic drug"
                  </span>
                  means the generic drug designated under section 3.1 (1) as the exclusive generic drug for an LCA category;
               </p>
               <p class="reference">
                  <a name="pit2">
                  </a>
                  Section 1 (1) definition of "generic drug inclusion or exclusion" was added by BC Reg 22/2019, effective April 1, 2019.
               </p>
               <p class="reference">
                  <a name="pit2">
                  </a>
                  Section 1 (1) definition of "manufacturer's list price" BEFORE amended by BC Reg 22/2019, effective April 1, 2019.
               </p>
               <p class="def" id="d2e204" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <span class="normal-bold-style" id="manufacturer's+list+price">
                     "manufacturer's list price"
                  </span>
                  means the price per unit of a drug, as provided by a manufacturer to the minister in the manner and at the time required by the minister;
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit3">
                  </a>
                  Section 3 (2) (d) was added by BC Reg 22/2019, effective April 1, 2019.
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit4">
                  </a>
                  Section 3.01 was enacted by BC Reg 22/2019, effective April 1, 2019.
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit5">
                  </a>
                  Section 3.1 was enacted by BC Reg 266/2016, effective April 1, 2017.
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit6">
                  </a>
                  Section 3.1 BEFORE repealed by BC Reg 22/2019, effective April 1, 2019.
               </p>
               <div class="section" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="section3.1">
                  </a>
                  <h4>
                     <a name="section3.1">
                     </a>
                     Exclusive generic drug in low cost alternative category
                  </h4>
                  <p class="sec" id="d0e579">
                     <span class="secnum">
                        <span class="secnumholder">
                           <b>
                              3.1
                           </b>
                           <a name="d0e587">
                           </a>
                           (1)
                        </span>
                     </span>
                     For the purposes of the LCA program, the minister may, for a specified period, designate one generic drug as the exclusive generic drug for an LCA category if all of the following apply:
                  </p>
                  <p class="para">
                     <a name="d0e595">
                     </a>
                     <span class="num">
                        <span class="holder">
                           (a)
                        </span>
                     </span>
                     all of the generic drugs in the LCA category are provisional drugs;
                  </p>
                  <p class="para">
                     <a name="d0e604">
                     </a>
                     <span class="num">
                        <span class="holder">
                           (b)
                        </span>
                     </span>
                     the manufacturer's list price for the exclusive generic drug is equal to or less than the maximum accepted list price for drugs in the LCA category;
                  </p>
                  <p class="para">
                     <a name="d0e613">
                     </a>
                     <span class="num">
                        <span class="holder">
                           (c)
                        </span>
                     </span>
                     the minister is of the opinion that there will be a sufficient supply of the exclusive generic drug for the entire designation period.
                  </p>
                  <p class="sub">
                     <a name="d0e623">
                     </a>
                     <span class="num">
                        <span class="holder">
                           (2)
                        </span>
                     </span>
                     The minister may not specify a designation period, for an exclusive generic drug, that exceeds 12 months.
                  </p>
                  <p class="sub">
                     <a name="d0e632">
                     </a>
                     <span class="num">
                        <span class="holder">
                           (3)
                        </span>
                     </span>
                     If the minister designates a generic drug as the exclusive generic drug for an LCA category, the minister must immediately cancel a determination, made under section 3 (1) (b), to include any other generic drug in the LCA category.
                  </p>
                  <p class="sub">
                     <a name="d0e641">
                     </a>
                     <span class="num">
                        <span class="holder">
                           (4)
                        </span>
                     </span>
                     A cancellation under subsection (3) may be made without notice to anyone or an opportunity to be heard.
                  </p>
                  <p class="hnote">
                     [en. B.C. Reg. 266/2016, Sch. 2, s. 2.]
                  </p>
               </div>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit7">
                  </a>
                  Section 4 (2) (a) BEFORE amended by BC Reg 344/2012, effective April 1, 2014.
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e552">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (a)
                     </span>
                  </span>
                  for an LCA category consisting of drugs available as oral solids only, 25%;
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit8">
                  </a>
                  Section 4 (2) BEFORE amended by BC Reg 22/2019, effective April 1, 2019.
               </p>
               <p class="sub" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e543">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (2)
                     </span>
                  </span>
                  Except as set out in subsections (3) and (4), the maximum accepted list price for drugs in an LCA category is the following percentage of the manufacturer's list price, as of the date on which a generic drug is first assigned to the LCA category, for the LCA drug comparator for that LCA category:
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e5521">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (a)
                     </span>
                  </span>
                  for an LCA category consisting of drugs available as oral solids only, 20%;
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e562">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (b)
                     </span>
                  </span>
                  for any other LCA category, 35%.
               </p>
               <p class="reference">
                  <a name="pit8">
                  </a>
                  Section 4 (2.1) was added by BC Reg 22/2019, effective April 1, 2019.
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit9">
                  </a>
                  Section 5 (2) (a) BEFORE amended by BC Reg 344/2012, effective April 1, 2014.
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e619">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (a)
                     </span>
                  </span>
                  if the LCA category consists of drugs available as oral solids only, 25% of the base price set out in Column 2 of the Schedule opposite the LCA category, and
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit10">
                  </a>
                  Section 5 (2) BEFORE amended by BC Reg 22/2019, effective April 1, 2019.
               </p>
               <p class="sub" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e610">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (2)
                     </span>
                  </span>
                  Except as set out in subsection (3), the maximum accepted list price for drugs in an LCA category listed in Column 1 of the Schedule is,
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e6191">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (a)
                     </span>
                  </span>
                  if the LCA category consists of drugs available as oral solids only, 20% of the base price set out in Column 2 of the Schedule opposite the LCA category, and
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e629">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (b)
                     </span>
                  </span>
                  for any other LCA category, 35% of the base price set out in Column 2 of the Schedule opposite that LCA category.
               </p>
               <p class="reference">
                  <a name="pit10">
                  </a>
                  Section 5 (4) (b) BEFORE amended by BC Reg 22/2019, effective April 1, 2019.
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e668">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (b)
                     </span>
                  </span>
                  for the purposes of section 4 (2), the date on which a generic drug is first assigned to the LCA category is deemed to be the date on which the minister deems the LCA category to have been established.
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit11">
                  </a>
                  Section 6 (1) BEFORE amended by BC Reg 255/2015, effective January 1, 2016.
               </p>
               <p class="sub" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e686">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (1)
                     </span>
                  </span>
                  The following are reference drug categories for the purposes of the reference drug program:
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e695">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (a)
                     </span>
                  </span>
                  angiotensin converting enzyme inhibitors;
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e704">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (b)
                     </span>
                  </span>
                  dihydropyridine calcium channel blockers;
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e714">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (c)
                     </span>
                  </span>
                  histamine 2 receptor antagonists;
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e723">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (d)
                     </span>
                  </span>
                  oral nitrates;
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e732">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (e)
                     </span>
                  </span>
                  non-steroidal anti-inflammatory drugs.
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit12">
                  </a>
                  Section 14 (1) BEFORE amended by BC Reg 266/2016, effective April 1, 2017.
               </p>
               <div class="section" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="section14">
                  </a>
                  <h4>
                     <a name="section14">
                     </a>
                     Designation of provisional drugs
                  </h4>
                  <p class="sec" id="d2e1409">
                     <span class="secnum">
                        <span class="secnumholder">
                           <b>
                              14
                           </b>
                           <a name="d2e1417">
                           </a>
                           (1)
                        </span>
                     </span>
                     The minister may designate a generic drug as a provisional drug if any of the following apply:
                  </p>
               </div>
               <p class="reference">
                  <a name="pit12">
                  </a>
                  Section 14 (1.1) was added by BC Reg 266/2016, effective April 1, 2017.
               </p>
               <p class="reference">
                  <a name="pit12">
                  </a>
                  Section 14 (2) BEFORE amended by BC Reg 266/2016, effective April 1, 2017.
               </p>
               <p class="sub" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e1478">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (2)
                     </span>
                  </span>
                  The minister may cancel a designation made under this section at any time without notice to anyone or an opportunity to be heard.
               </p>
               <p class="reference">
                  <a name="pit12">
                  </a>
                  Section 14 (3) BEFORE amended by BC Reg 266/2016, effective April 1, 2017.
               </p>
               <p class="sub" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e1487">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (3)
                     </span>
                  </span>
                  If a drug's designation as a provisional drug is cancelled under subsection (2), the minister must not list the drug on a formulary before the next April 1, unless section 16
                  <em>
                     [temporary listing of drugs]
                  </em>
                  applies.
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit13">
                  </a>
                  Section 14 (1.1) (a) BEFORE repealed by BC Reg 22/2019, effective April 1, 2019.
               </p>
               <p class="para" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d0e1709">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (a)
                     </span>
                  </span>
                  if the minister has designated, under section 3.1 (1), an exclusive generic drug for an LCA category, the minister must immediately cancel a designation made under this section in respect of any other generic drug assigned to the LCA category;
               </p>
               <p class="reference">
                  <a name="pit13">
                  </a>
                  Section 14 (3) BEFORE repealed by BC Reg 22/2019, effective April 1, 2019.
               </p>
               <p class="sub" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e14871">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (3)
                     </span>
                  </span>
                  If, under subsection (1.1) (a), the minister cancels the designation of a drug that has been assigned to an LCA category, the minister must not list the drug on a formulary during the designation period.
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit14">
                  </a>
                  Section 15 (3) BEFORE amended by BC Reg 266/2016, effective April 1, 2017.
               </p>
               <p class="sub" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e1566">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (3)
                     </span>
                  </span>
                  If a drug's listing is refused or cancelled under subsection (2), the minister must not list the drug on a formulary before the next April 1, unless section 16
                  <em>
                     [temporary listing of drugs]
                  </em>
                  applies.
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit15">
                  </a>
                  Section 15 (3) BEFORE repealed by BC Reg 22/2019, effective April 1, 2019.
               </p>
               <p class="sub" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="d2e15661">
                  </a>
                  <span class="num">
                     <span class="holder">
                        (3)
                     </span>
                  </span>
                  During the designation period, the minister must refuse to list on a formulary a drug described in subsection (1) that would be assigned to an LCA category if the minister has designated, under section 3.1 (1), an exclusive generic drug for the LCA category.
               </p>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit16">
                  </a>
                  Section 17 BEFORE amended by BC Reg 344/2012, effective March 1, 2014.
               </p>
               <div class="section">
                  <h4>
                     <a name="section17">
                     </a>
                     Manufacturers to sell at new prices
                  </h4>
                  <p class="sec2">
                     <span class="secno">
                        <strong>
                           17
                        </strong>
                     </span>
                     On or after March 1, 2013, a manufacturer must not sell a generic drug that is subject to the LCA program to suppliers or providers at a price higher than what the manufacturer's list price for the drug is or will be as of April 1, 2013.
                  </p>
               </div>
            </div>
            <div class="pit" width="100%">
               <p class="reference">
                  <a name="pit17">
                  </a>
                  Section 17 BEFORE amended by BC Reg 10/2016, effective January 29, 2016.
               </p>
               <div class="section" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="section17">
                  </a>
                  <h4>
                     <a name="section17">
                     </a>
                     Manufacturers to sell at new prices
                  </h4>
                  <p class="sec nosubsecnum" id="d2e1643">
                     <span class="secnum">
                        <span class="secnumholder">
                           <b>
                              17
                           </b>
                        </span>
                     </span>
                     On or after March 1, 2014, a manufacturer must not sell a generic drug that is subject to the LCA program to suppliers or providers at a price higher than what the manufacturer's list price for the drug is or will be as of April 1, 2014.
                  </p>
                  <p class="hnote">
                     [am. B.C. Reg. 344/2012, s. (c).]
                  </p>
               </div>
            </div>
            <div class="pitlast" width="100%">
               <p class="reference">
                  <a name="pit18">
                  </a>
                  Part 4 BEFORE repealed by BC Reg 266/2016, effective April 1, 2017.
               </p>
               <p class="part" id="d2e1634" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="part4">
                  </a>
                  Part 4 — Sale of Drugs by Manufacturers
               </p>
               <div class="section" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:xlink="http://www.w3.org/1999/xlink">
                  <a name="section17">
                  </a>
                  <h4>
                     <a name="section17">
                     </a>
                     Manufacturers to sell at new prices
                  </h4>
                  <p class="sec nosubsecnum" id="d2e1649">
                     <span class="secnum">
                        <span class="secnumholder">
                           <b>
                              17
                           </b>
                        </span>
                     </span>
                     On or after March 1, 2016, a manufacturer must not sell a generic drug that is subject to the LCA program to suppliers or providers at a price higher than what the manufacturer's list price for the drug is or will be as of April 1, 2016.
                  </p>
                  <p class="hnote">
                     [am. B.C. Regs. 344/2012, s. (c); 10/2016.]
                  </p>
               </div>
            </div>
         </div>
      </div>
   </body>
</html>
